Streetbeat News

Products Services

LGND

Ligand Pharmaceuticals (NASDAQ:LGND) has launched Pelthos Therapeutics to commercialize ZELSUVMI, a novel drug for treating molluscum contagiosum. Scott Plesha is appointed CEO of Pelthos. ZELSUVMI, developed with NITRICIL technology, is expected to be available in the US by late 2024. Ligand acquired ZELSUVMI's rights from Novan, Inc. in September 2023. Ligand aims to commercialize ZELSUVMI with partners, continuing its strategy of maximizing value through equity and royalty rights in new entities.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 1:05 pm

LBPH

Longboard Pharmaceuticals is set to present Phase 1b/2a clinical data from its PACIFIC Study at the AAN Annual Meeting on April 15. The data will also be featured in an encore presentation at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 1:05 pm

SPRY

ARS Pharmaceuticals has submitted a response to the FDA's Complete Response Letter (CRL) for neffy, addressing all additional requests including positive data from a repeat dose PK/PD study and updated testing showing no measurable nitrosamine levels. The submission triggers a review period of up to six months by the FDA.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 1:04 pm

ALLE

GOOG

GOOGL

Allegion has expanded its mobile credential offerings by integrating Schlage employee badges with Google Wallet, aiming to enhance security and convenience for staff. This collaboration between Allegion and Google signifies a step forward in leveraging technology for secure and efficient workplace access solutions.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 1:01 pm

HSDT

Helius Medical Technologies Inc (NASDAQ:HSDT) announced a partnership with Lovell Government Services to make its PoNS device available to federal healthcare systems, leading to a significant stock price increase. The device, indicated for gait deficit treatment in mild-to-moderate multiple sclerosis, has shown promising real-world results. Additionally, the company received HCPCS codes for the PoNS controller and is seeking marketing authorization for stroke treatment in the U.S.

Portfolio Pulse from Vandana Singh

April 03, 2024 | 12:55 pm

PINC

Beebe Healthcare has chosen Premier Inc. (PINC) as its strategic partner for supply chain operations. This partnership aims to enhance Beebe Healthcare's supply chain efficiency and reduce operational costs.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:54 pm

BABA

INTC

TSLA

TSM

XPEV

Cryptocurrencies like Bitcoin, Ethereum, and Dogecoin are experiencing a dip amid high selling pressure, with analysts suggesting Bitcoin won't see highs unless it breaks $69K. Tesla is shifting investor focus to its energy business amid an auto slowdown. ARK's Bitcoin ETF sees a record outflow, and Intel, XPeng stocks move lower. Alibaba announces a $4.8B stock repurchase, and TSMC suspends chip production due to a tremor in Taiwan. Tesla faces criticism and potential fourth session of losses, while Geely's Zeekr revives IPO plans.

Portfolio Pulse from Akanksha Bakshi

April 03, 2024 | 12:50 pm

VNDA

Vanda Pharmaceuticals Inc's (NASDAQ:VNDA) Fanapt (iloperidone) tablets received FDA approval for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This approval expands Fanapt's market, previously approved for schizophrenia treatment since 2009. Bipolar disorder affects approximately 2.8% of the U.S. adult population, with a significant portion classified as severe. The approval was based on a pivotal study showing statistically significant improvement in patients treated with Fanapt over placebo. Despite this positive development, Vanda's net product sales for 2023 decreased by 4% Y/Y, with sales of another major drug, Hetlioz, declining due to increased competition. VNDA shares surged 27.9% in premarket trading following the announcement.

Portfolio Pulse from Vandana Singh

April 03, 2024 | 12:48 pm

SRZN

Surrozen has published a study in 'Respiratory Research' showcasing the potential of its Wnt mimetic technologies in treating pulmonary fibrosis. This development could mark a significant step forward in the treatment of this condition, potentially impacting Surrozen's market position and future revenue streams.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:41 pm

VRNT

Verint has expanded its partnership with Webex by Cisco, integrating Verint Open Platform's Unified Data Hub into the Webex App Hub. This integration aims to enhance customer experience (CX) automation through the Webex Contact Center.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:37 pm